Key result
Nesiritide was shown to be similar or significantly more effective than standard therapy at improving the status of patients with decompensated heart failure while demonstrating cost savings.
Why the study?
Is nesiritide clinically and cost-effective compared to standard therapy in patients with decompensated heart failure?
Is nesiritide clinically and cost-effective compared to standard therapy in patients with decompensated heart failure?
This review suggests nesiritide is a clinically effective and cost-saving treatment option for acutely decompensated heart failure compared to standard therapies.
No takes yet. Share an insight, caveat, or question.
May support nesiritide for cost savings in decompensated HF; leaves open confirmation in prospective trials.
Lenz et al. (2005) conducted a review in Decompensated heart failure. Nesiritide vs. Placebo and nitroglycerin / standard therapy was evaluated. Nesiritide was shown to be similar or significantly more effective than standard therapy at improving the status of patients with decompensated heart failure while demonstrating cost savings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: